版本:
中国

BRIEF-Galapagos announces three new phase 2 Proof-of-Concept studies with filgotinib

April 4 Galapagos NV:

* Galapagos announces three new phase 2 Proof-of-Concept studies with filgotinib

* Trials for filgotinib in Sjögren's syndrome, in ankylosing spondylitis (as), and in psoriatic arthritis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐